Ghobadi on the Correlation Between CD8/CD4 Ratio and Responses to Blinatumomab in Patients With DLBCL

Ghobadi explained an interesting correlation found in the results of his study presented at the 2020 ASH Annual Meeting & Exposition.

In an interview with CancerNetwork®, Armin Ghobadi, MD, of the Washington University School of Medicine in St. Louis, Missouri, explained the association between a higher CD8/CD4 ratio for patients with diffuse B-cell lymphoma who were still in remission at the median follow-up and durable responses after blinatumomab (Blincyto) treatment in a study (NCT03072771) presented at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.


When we looked at those who are still in remission up to 15 months later versus those who relapsed, interestingly, we found out that the ratio of CD8 to CD4 before they started blinatumomab and after BEAM [carmustine, etopside, cytarabine, and melphan] and autologous transplant was significantly higher in those patients still in remission 15 months later. And that has been reported in other studies. Basically, blinatumomab [is] bringing in T-cells, effector cells, to go after the lymphoma cells. And in this case, having a higher ratio of CD8 to CD4 was associated with durable response even after 1 cycle of blinatumomab.

Related Videos
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Vanderbilt University Medical Center says that patients with relapsed/refractory multiple myeloma may be able to live a normal life following response to salvage treatment with bispecific monoclonal antibodies.
Andre H. Goy, MD, an expert on B-cell malignancies
Andrew Ip, MD, an expert on B-cell malignancies
Andrew Ip, MD, an expert on B-cell malignancies
Andrew Ip, MD, an expert on B-cell malignancies
Andrew Ip, MD, an expert on diffuse large B-cell lymphoma
Related Content